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Abstract
Transplantation of freshly-aspirated autologous bone marrow, together with a scaffold, is a
promising clinical alternative to harvest and transplantation of autologous bone for treat-
ment of large defects. However, survival proliferation, and osteogenic differentiation of the
marrow-resident stem and progenitor cells with osteogenic potential can be limited in large
defects by the inflammatory microenvironment. Previous studies using EGF tethered to syn-
thetic polymer substrates have demonstrated that surface-tethered EGF can protect human
bone marrow-derived osteogenic stem and progenitor cells from pro-death inflammatory
cues and enhance their proliferation without detriment to subsequent osteogenic differentia-
tion. The objective of this study was to identify a facile means of tethering EGF to clinically-
relevant βTCP scaffolds and to demonstrate the bioactivity of EGF tethered to βTCP using
stimulation of the proliferative response of human bone-marrow derived mesenchymal stem
cells (hBMSC) as a phenotypic metric. We used a phage display library and panned against
βTCP and composites of βTCP with a degradable polyester biomaterial, together with
orthogonal blocking schemes, to identify a 12-amino acid consensus binding peptide
sequence, LLADTTHHRPWT, with high affinity for βTCP. When a single copy of this βTCP-
binding peptide sequence was fused to EGF via a flexible peptide tether domain and
expressed recombinantly in E. coli together with a maltose-binding domain to aid purifica-
tion, the resulting fusion protein exhibited modest affinity for βTCP. However, a fusion pro-
tein containing a linear concatamer containing 10 repeats of the binding motif the resulting
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fusion protein showed high affinity stable binding to βTCP, with only 25% of the protein
released after 7 days at 37oC. The fusion protein was bioactive, as assessed by its abilities
to activate kinase signaling pathways downstream of the EGF receptor when presented in
soluble form, and to enhance the proliferation of hBMSC when presented in tethered form
on commercial βTCP bone regeneration scaffolds.
Introduction
Bone grafting procedures in the USA top the half-million mark annually and 2.2 million world-
wide [1,2]. They represent an approximate 1.5 billion dollar industry in the USA alone [1,2].
These procedures are a requirement for healing of critically-sized bone defects, including non-
unions, cavities and segmental defects. Within the spectrum of bone grafting alternatives,
autogenous cancellous bone graft is the most common treatment of non-unions (40–50%) [1–
3]. Autologous bone is the gold standard in treatment of non-mineralized matrix as it is a vas-
cularized graft that provides osteogenic cells with proper osteoinductive stimulus that enhances
cell-mediated repair. However, the available amount of autologous bone is often insufficient to
treat large defects and the primary alternative graft approach, cadaver bone, has clinical short-
comings ranging from risk of disease transmission to relatively poor long-term function.
Synthetic scaffolds that can recapitulate the ability of autologous bone to promote bone
regeneration would therefore be of great benefit in the clinic. Such scaffolds would eliminate
the need to harvest bone from patients and might allow graft properties to be tailored for indi-
vidual patient needs. Unfortunately, most synthetic grafts, although osteoconductive, fall far
short of the performance level of autogenous bone or cancellous allografts, as they lack proper
vascularization, osteoprogenitor cells, and/or osteoinductive cues. Osteoprogenitor cells differ-
entiate into osteoblasts and produce the bone matrix (osteoid) that later mineralizes and is
remodeled into lamellar bone, hence these cells are essential for bone regeneration. Osteopro-
genitor cells arise from differentiation of connective tissue progenitors (CTPs) [1,4], a hetero-
geneous population that includes multipotent mesenchymal stem cells (MSCs) [5–7].
Osteoinductive cues are important in synthetic grafts as they can help recruit and stimulate
near-by, tissue-resident stem and progenitor cells to participate in the regeneration process.
However, in many defect situations, the local environment is relatively depleted of stem and
progenitor cells and thus supplementation of the graft with these essential cells is likely neces-
sary to ensure healing.
CTPs are present in bone marrow aspirates, making marrow an attractive therapeutic
source of osteogenic precursors when stem and progenitor cells for graft augmentation. Opti-
mization of CTP isolation [4] and transplantation strategies [8–10] has led to improved bone
healing in animal models [9,11–13]. However, the hypoxic, nutrient-limited, and inflammatory
microenvironment of the bone wound can cause death of a substantial fraction of transplanted
cells within the first few days [14–17], reducing the effective number of osteoprogenitors that
contribute to the proliferative and remodeling stage of wound healing [18]. We thus hypothe-
size that providing bioactive cues that stimulate survival and proliferation of connective tissue
progenitors within grafts, without interrupting terminal osteogenic differentiation, will
improve the outcome of bone healing [1,3,18,19].
Epidermal growth factor (EGF) stimulates colony formation and proliferation of CTPs and
MSCs in vitro without interfering with subsequent osteogenic differentiation [20–24]. EGF
binds to the EGF receptor (EGFR), an essential regulator of both bone development and bone
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tissue homeostasis [25–27]. However, EGF drives EGFR internalization, resulting in downre-
gulation of EGFR and ligand desensitization when cells are exposed to moderately high ligand
concentrations (i.e., above the KD for ligand-receptor interactions, ~1nM) [28,29].
Receptor downregulation can be avoided by presenting EGF in tethered rather than soluble
form, such that it binds to the EGFR but the EGF-EGFR complex is physically restrained from
internalization and downregulation by the tether that links EGF to the culture substrate. Such
tethered presentation restricts EGFR signaling to the cell membrane, resulting in sustained
EGFR activation and different patterns of intracellular signaling and phenotypic responses
compared to soluble EGF [30,31]. MSC spreading [31] and migration [32] are enhanced with
tethered compared to soluble EGF. A particularly attractive MSC phenotype elicited by teth-
ered EGF, but not soluble EGF, is protection of MSC from pro-death hypoxia and inflamma-
tory cytokine cues [31,33] while preserving proliferative and osteogenic potential [30,31,33,34].
This collection of beneficial effects of tethered EGF on cultured MSCs and CTPs suggests that
modifying scaffolds with tethered EGF may enhance bone formation by transplanted CTPs by
protecting them from death and stimulating proliferation.
Beta-tri calcium phosphate (ßTCP) scaffolds and composites thereof serve as a substrate for
tissue-resident or transplanted MSCs or CTPs, evidenced by their performance in numerous
animal studies [35–38] and its current use in a variety of bone void fillers in the clinic [39–41].
However, ßTCP does not have any intrinsic biological stimulatory activity and is not amenable
to covalent conjugation of biomolecules. Modification of ßTCP scaffolds is thus limited to
adsorption/freeze drying strategies, which often result in bolus release due to the relatively low
affinity of biomolecules for the ßTCP surface.
High–affinity binding peptides, derived from combinatorial screens of peptide libraries
against the surface of interest, are an appealing means to tether proteins to surfaces that lack
functional groups for covalent modification [42–45]. High affinity peptides identified by
screening are fused to the ligand of interest by a peptide tether, thus creating a fusion protein
that binds to the surface with high affinity and presents the ligand in an accessible, bioactive
form.
Here, we report the results of our screen of a commercial 12-mer phage display library to
identify a high affinity ßTCP binding peptide. We used protein fusion to link the binding pep-
tide to the human EGF domain. Further, we describe an efficient scheme to concatamerize the
binding peptide and show that concatamerization up to a 10-mer increases the affinity of the
EGF fusion protein for ßTCP. The bioactivity of EGF tethered to clinically-approved ßTCP
scaffolds was demonstrated by assessing the plating efficiency and in vitro proliferative
response of human MSC over 7 days in culture.
Materials and Methods
Fabrication of ßTCP and ßTCP-polymer composite scaffolds
Scaffolds were fabricated at Integra Life Sciences (Plainsboro, NJ, USA) from either ßTCP or a
composite of ßTCP and polylactide-co-glycolide (PLGA) using the TheriForm 3D rapid proto-
typing platform [46]. Briefly, to create ßTCP scaffolds, granulated ßTCP powder was sintered
and sieved to<106 μm. Scaffolds were fabricated in the shape of a cross by depositing binder
in a programmed sequence onto a powder bed containing a mixture of sintered ßTCP powder
and porogen (spray-dried lactose powder). The scaffolds were then sintered for 20 h, dried for
1 day, leached for 2 days to remove porogen, and dried one day to yield crosses measuring
5.4x5.4x2.7mm (Fig 1A).
Scaffolds have an open porous architecture (Fig 1B) with a pore volume of about 60%
porous and a mean pore diameter of 60μm (range of 5–900μm). Chemically, the scaffolds are
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approximately >95% ßTCP with the remaining portion being other resorbable forms of cal-
cium phosphate. Composite ßTCP-PLGA scaffolds were fabricated in a similar fashion by mix-
ing powders with a porogen (spray-dried lactose powder). Composite scaffolds were fused by
exposure to chloroform vapor, leached, dried, and sterilized by ethylene oxide as described else-
where [47]. The selection of size of scaffold was based on compatibility with existing tissue cul-
ture systems such as multi-well plates. The selection of geometry was made in an attempt to
reduce the ratio of scaffold internal surface area to culture medium volume. A space filling
shape such as a cube or cylinder would offer a higher internal surface area relative to the total
culture volume in a multi-well plate. This would have led to more rapid medium depletion. A
cross shape such as the one used in this study presents a lower total internal surface area and
thus a lower nutritional burden per unit volume of medium. This allowed for longer culture
times between medium changes (ranging between 1–3 days). A cube or cylinder geometry
would have required media passages every 12–18 hours at the higher cell densities).
Scanning electron micrographs of the ßTCP scaffolds were obtained using a Jeol 5600LV
Scanning Electron Microscope. Samples were mounted on stubs, sputter coated with Au/Pd
(~5nm layer) and imaged at the desired magnifications using an accelerating voltage of 5 kV.
Phage display against ßTCP scaffolds
Pure ßTCP cross-shaped scaffolds (5.4x5.4x2.7mm) from Integra Life Sciences (Plainsboro, NJ,
USA) were crushed into powder, autoclaved for 35 minutes at 121°C and stored under dry ster-
ile conditions prior to all experiments. The resulting sterile ßTCP powder was blocked for 24
hours at 4°C under moderate agitation with either sterile filtered Odyssey Blocking Buffer
(OBB; non-mammalian blocking buffer; LI-COR; Lincoln, NE, USA) or 5% bovine serum albu-
min in phosphate buffered saline (BSA; Sigma-Aldrich, St. Louis, MO, USA). Blocked ßTCP
was pelleted at 2000 RPM for 2 minutes, washed 3X with PBS then subjected to three rounds of
phage display using the New England Biolabs linear 12-mer Ph.D. kit (Ipswich, MA, USA).
Orthogonally blocked ßTCP (i.e. blocked with BSA vs. OBB) provided a control against
Fig 1. Structures of ßTCP scaffolds and EGF-ßTCP binding peptide (BP-T-EGF) fusion protein.
Macroscopic appearance of a 5mm ßTCP Therilok cross-shaped scaffold used for cell culture experiments
(A). These scaffolds were crushed to a coarse powder for phage panning to select binding peptides. SEM
micrographs of the surface of ßTCP scaffolds at low, intermediate and high resolution as indicated by scale
bars (B), Structure of the fusion protein “BP10-T-EGF” comprising the 12-amino acid ßTCP-binding peptide
fused to EGF by flexible protease-resistant tethers flanking a coil domain (C; see S1 Table for specific
sequence).
doi:10.1371/journal.pone.0129600.g001
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panning against components of the blocking buffers. Additional controls included a
ßTCP-PLGA composite cross-shaped scaffold (5.4x5.4x2.7mm), crushed into powder, simi-
larly blocked with BSA as well as a mock tube to control against panning against tube compo-
nents. After three rounds of panning, ten plaques from each of the ßTCP/BSA and
ßTCP-PLGA/OBB and nine from the ßTCP/OBB block condition were picked, amplified, then
sequenced (the mock condition and the ßTCP-PLGA blocked with BSA did not produce pla-
ques after the second and third round, respectively). Sequences were analyzed for consensus
using JalView Multiple Sequence Alignment Editor.
Mutagenesis to create multimeric ßTCP-binding peptide domains in
EGF fusion proteins
We had previously created a pMAL-c5X vector (New England Biolabs, Ipswich, MA, USA)
expressing human EGF in fusion with various epitopes [48]. Building on this, the highest-ranked
sequence from all the sequenced third round phage display panning (LLADTTHHRPWT)
against ßTCP was serially cloned into a pMAL expression cassette using PCRmutagenesis and a
short primer to generate a library of multimer insertions fused to EGF via protease-resistant teth-
ers flanking a coil domain (Fig 1C). PCR mutagenesis was performed with a Quickchange Light-
ning II kit (Agilent, Santa Clara, CA, USA). PCR primers were designed to prime wholly within
the ßTCP-binding peptide coding region thus allowing multiple insertions during a single PCR
mutagenesis round. Multimer clones were sequenced to confirm DNA identity with target
sequence, transformed into BL21(DE3)pLysS E. coli (Cat# 200132; Agilent, Santa Clara, CA,
USA) and plated on ampicillin LB agar. We designate the final gene product produced recombi-
nantly as BPn-T-EGF where n denotes the number of ßTCP-binding peptide repeats in the bind-
ing domain and n ranged from 1–10.
Protein expression
Protein was expressed in 1L BL21(DE3)pLysS E. coli (Cat# 200132; Agilent, Santa Clara, CA,
USA) cultures grown in ampicillin-containing (50μg/mL) luria broth (LB) at 250 rpm, 37°C
until OD (600nm) = 0.6, then induced with IPTG and incubated at 22°C for 4 hours. Proteins
were harvested by pelleting cultures at 3700 RPM on an Allegra G3.8 rotor at 4°C for 30 min-
utes then freezing the pellet at -80°C overnight followed by cell lysis using Bugbuster Reagent
(EMDMillipore, Billerica, MA, USA) supplemented with PMSF and protease inhibitor cocktail
(Complete Protease Mini; Roche Diagnostics Corp, Indianapolis, IN, USA). Lysed cells were
centrifuged at 3700 RPM on an Allegra G3.8 rotor at 4°C for 1 hour. The supernatant was then
diluted 1:4 in tris-buffered saline and subjected to maltose binding protein affinity chromatog-
raphy in accordance with the manufacturer’s instructions (New England Biolabs, Ipswich, MA,
USA). Eluted fractions were pooled and subjected to ultrafiltration through a 50,000 MWCO
membrane U-tube concentrator (Novagen). The protein solution was then sterile filtered
through a 0.2 μm syringe filter. Purity was confirmed by SDS-PAGE using coomassie staining.
Typical purity of the full length fusion protein (73 kDa) comprising MBP, ten concatamerized
ßTCP-binding peptide motifs, the tether-coil domain, and EGF, i.e., BP10-T-EGF, ranged from
75% to 90%, with>99% of the protein being of recombinant nature. Contaminant protein was
BP10-T-EGF lacking the EGF motif (BP10-T). Similar results were observed for all concatamer
lengths of binding peptide. Stock protein quantification was performed using a Nanodrop ND-
2000 spectrophotometer at 280nm absorbance. The absorbance values along with the predicted
extinction coefficient obtained through the ExPASy protparam tool (http://web.expasy.org/
protparam; the full protein sequence as input) were used to calculate the protein concentration.
Concentrated protein stocks were used immediately or stored for a week at 4°C.
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Characterization of BPn-T-EGF binding to and elution from ßTCP
scaffolds
ßTCP scaffolds or sieved pure ßTCP powder were incubated at room temperature for two
hours in purified BPn-T-EGF diluted in OBB buffer. After incubation, scaffolds or powder
were washed three times in three volumes of 20 mM Tris-buffered saline at pH 7.4 followed by
a final wash and storage in PBS. Relative binding as a function of concatamer length and pep-
tide concentration was determined by eluting ßTCP-bound BPn-T-EGF in 200 μL of pH 2.2
0.2M glycine buffer + 1mg/mL BSA for two hours, then analyzing the eluate by Western blot
coupled with IR-dye immunofluorescence (1° Ab—Rabbit Anti-hEGF {Abcam, Cambridge,
MA, USA; cat#ab9695}; 2° Ab Goat Anti-rabbit-AlexaFluor680 {Invitrogen–Life Technologies;
Grand Island, NY, USA; cat# A-21109}). Control “–T-EGF” protein incorporating all elements
of the BPn-T-EGF except the ßTCP-binding peptide region was used as a negative control for
non-specific binding in all experiments. This negative “–T-EGF” control did not show detect-
able binding to ßTCP.
For the binding isotherms, 3mm and 5mm crosses were incubated with BP10-T-EGF protein
solutions ranging from 0.2–9μM for ~36 hours at 4°C. After tethering, the crosses were washed
2x with PBS then assayed for total protein by the BCA assay. To ensure that samples were
within the linear range of the BCA assay, crosses tethered with BP10-T-EGF at the higher end
of the concentration range were divided into multiple segments and placed in individual wells
of either 96-well plates or 48-well plates as follows: 0.2μM (1:1), 1μM (1:2), and 2μM (1:3) con-
ditions for the 3mm scaffolds and the 0.4 μM (1: 2) condition for the 5mm cross were per-
formed in 96 well plates; the 5μM condition for the 3mm cross (1:1) and the 2μM (1:1) and
9μM (1:2) conditions for the 5mm crosses were performed in 48 well plates. Water (100μL, 96
well; 400μL, 48 well) water was added to the wells with scaffolds/fragments, which were then
crushed into semi-powder form (no large granules or scaffold blocks visible). The BCA reagent
was then added to all wells (100μL for 96 well and 400μL for 48 well), the plates were sealed
with plastic adhesive and incubated at 37°C for 50 minutes. After incubation, the plates were
centrifuged for 10 minutes at 2,000 RPM at room temperature. The well plates were then gently
tilted and 100μL out of each well was moved to a new 96 well plate, being careful not to take
any ßTCP powder in the process. The final plate was checked to ensure that all wells were free
from bubbles and the plate was read at 562nm. Background from wells without crosses or pro-
tein was used to correct for background absorbance. We confirmed that ßTCP (in scaffold or
powder form) did not change the background absorbance of the BCA reagent solution. Abso-
lute protein amounts in test wells were calculated based standard curves using BP10-T-EGF,
where the ratio of the slope of the BP10-T-EGF over BSA standard curve was 1.5–1.6.
To close the mass balance, BP10-T-EGF protein concentrations remaining in the superna-
tant after the tethering process were measured via both Nanodrop (absorption at 280 nm) for
relatively concentrated samples (OD> 0.3) and the BCA assay across a range of concentra-
tions. Methods showed a strong correlation (ANOVA p-value>0.05) with no statistical differ-
ences and coefficients of variation of ~15%.
Cell culture
Human bone marrow mesenchymal stromal cells (hBMSCs) obtained at Passage 1 (Texas
A&MHealth Science Center College of Medicine's Institute for Regenerative Medicine) were
culture-expanded using expansion medium (EX) (αMEM with 2mM L-glutamine, 16.5% fetal
bovine serum (FBS, Atlanta Biologics; Flowery Branch, GA, USA), 100 units/ml of penicillin
and 100 μg/ml streptomycin) at low seeding density (50 cells/cm2) and frozen stocks were
made when cells reached 70–80% confluency to Passage 2 (“P2”; freezing media: αMEM with
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2mM L-glutamine, 16.5% FBS and DMSO mixed at a 65:30:5 v/v ratio). For the experiments,
P2 stocks were expanded at low density (50cells/cm2) and used for experiments when cells
reached 70–80% confluency.
Validation of bioactivity of the EGF domain in fusion proteins
The intrinsic activity of the EGF domain in fusion proteins was assessed by comparing the abil-
ity of soluble BP10-T-EGF and wild-type EGF to stimulate signaling activity downstream of
EGFR in hBMSC. Passage 3 hBMSCs were seeded onto Falcon 12-well tissue culture-treated
polystyrene plates (Becton Dickinson & Co.; Franklin Lakes, NJ, USA) at a density of 18,000
per well and grown to a monolayer by culturing in EM. The cells were then serum starved by
incubation overnight in 2% dialyzed FBS (Gibco–Life Technologies; Grand Island, NY, USA)
and after overnight incubation the cells were exposed to serum-free medium for 2hr prior to
experiment. The medium was aspirated and cells were exposed to serum-free media containing
the corresponding ligand or negative control (no ligand) for a period of 10 minutes. The media
were then aspirated, the plates were placed on ice and the wells were rinsed with ice cold 1xPBS
and then incubated with ice-cold lysis buffer (Bio-Rad, Philadelphia, PA, USA) that included
both protease inhibitors and phosphatase inhibitors used at 1x concentration (Complete Prote-
ase Mini and PhosSTOP phosphatase inhibitor tablets; Roche Diagnostics Corp, Indianapolis,
IN, USA). While on ice, wells were scraped with rubber policemen and lysates collected and
placed in the wells of a sterile, low protein binding 1.2μm filter 96-well plates (Multiscreen
HTS, low protein binding, EMDMillipore, Billerica, MA, USA) and placed on top of a regular
96-well plate and centrifuged at 2,000 rpm for 5 minutes. The plate was then sealed with a
microplate sealing film (Thermo Fisher Scientific; Pittsburgh, PA, USA) and stored at -80C or
used immediately. The BCA assay using BSA as a standard was used to measure lysate
concentrations.
Western blots for phosphor-ERK1/2 were performed by loading 10 μg of lysate into each
well of an SDS-PAGE gel (Nu-PAGE Novex 4–12% Tris-bis gel, 10-well; Invitrogen–Life Tech-
nologies, Grand Island, NY, USA). Proteins in the gel were then transferred to a Nitrocellulose
membrane (Bio-Rad, Philadelphia, PA, USA) using the X Cell II blot unit (Invitrogen–Life
Technologies; Grand Island, NY, USA). The membranes were blocked using OBB for 1hr at
room temperature (RT). After the blocking step, the blots were incubated overnight with the
primary antibodies (1° Ab) targeting phospho-ERK1/2 (Rabbit anti-phospho-ERK1/2
(Thr202/Tyr204) Ab cat #4370; from Cell Signaling in Danvers, MA, USA) and the loading
control GAPDH Ab (Mouse anti-GAPDH Ab, cat#AB9484; from Abcam in Cambridge, MA,
USA) diluted in 1xPBS containing 0.1% Tween-20 (T-20). The p-ERK1/2 antibody was diluted
1:1000 and the GAPDH antibody was diluted 1:2000 (stock is 1mg/mL; use at 0.5–1 μg/mL).
After 1° Ab incubation, the blots were washed 4x with 1xPBS containing 0.1% T-20 and incu-
bated with the secondary antibody (2° Ab) (1:10,000 dilution) tagged with IR-range dyes (700-
800nm; Goat anti-mouse-IR800 dye from LI-COR; Lincoln, NE, USA, and Goat anti-rabbit-
AlexaFluoro680 from Invitrogen–Life Technologies; Grand Island, NY, USA) in PBS with
0.1% T-20 and 0.01% SDS. The blots were then incubated in the Ab solutions for 45 minutes at
RT with gentle shaking. Blots were washed 4X, placed in neat 1xPBS and scanned at in a
LI-COR machine (700nm and 800nm channels). The intensities from each band (p-ERK1/2 at
700nm or GAPDH at 800nm) were measured using the Odyssey 3.0 software (LI-COR; Lin-
coln, NE, USA). All the intensity values for p-ERK1/2 were normalized to the GAPDH loading
control and then normalized to the no EGF controls (negative control). Results from all blots
(N = 3) were then averaged and plotted. For the westerns against the EGF domain of BPn-
T-EGF, a similar procedure was performed but using a Goat Anti-hEGF antibody (R&D
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systems, Minneapolis, MN, USA; cat# AB-236-NA) as the 1° Ab and a Donkey Anti-Goat
IRdye680RD (LI-COR; Lincoln, NE, USA; cat# 926–68074) as the 2° Ab.
hBMSC proliferation assays on ßTCP scaffolds
Cell proliferation was determined using the Alamar Blue (AB) assay (Invitrogen–Life Technol-
ogies; Grand Island, NY, USA) at 7 days post-seeding. Passage 3 hBMCSs were seeded at 2,000
cells per well onto 5mm ßTCP cross-shaped scaffolds (5.4x5.4x2.7mm; Therilok from Integra
Life Sciences, Plainsboro, NJ, USA). Cells in media were seeded into the center of the well
directly on top of the crosses (200uL total). This resulted in a seeding fraction of ~16–20% of
total cells seeded for 3mm crosses and ~31–42% for 5mm crosses, approximately comparable
to the cross sectional area of the crosses in the well. This agrees well with previous observations
that static seeding generally leads to low seeding densities unless the scaffold occupies most of
the well surface [49].
Following seeding, cells were cultured overnight in EX media. Crosses were then moved to
new wells to eliminate contributions from cells that had attached to the bottom of the well. The
crosses were then cultured in new plates for a cumulative time of 7 days in EX media. Each con-
dition was performed in triplicate. After the 7-day culture the cell-containing ßTCP scaffolds
(EGF-tethered and controls) were moved into a sterile, low-protein binding 1.2μm filter
96-well plate (Multiscreen HTS, low protein binding; EMDMillipore, Billerica, MA, USA) and
the Alamar Blue reagent (Invitrogen–Life Technologies; Grand Island, NY, USA) was then
added to each well (mixed in a 1 part of the 10x AB reagent to 1 part EX media according to
the manufacturer’s instructions). The plate was then incubated at 37°C, 5% CO2 for 4 hours
with gentle mixing. After incubation, the filter plate unit was attached on the bottom to a flat-
bottom 96-well plate and centrifuged at 1000 rpm for 3 minutes. This method allowed for com-
plete recovery of AB dye-media mixture. One-hundred microliters of the resulting AB dye-
media mixture collected was transferred to a new flat-bottom 96-well plate to be read by a
SpectraMax M2e multi-well fluorescent plate reader (Molecular Devices Corp.; Sunnyvale, CA,
USA) at a 570 nm excitation wavelength and 585 nm emission wavelength as recommended by
manufacturer’s instructions. The background fluorescence reading (AB solution in media with
a cell-free ßTCP scaffold) was subtracted from the AB fluorescence reading for each well to
obtain the net fluorescence. The average net AB fluorescence units from each condition (N = 3
per condition) were normalized to no EGF ligand condition (control).
Analysis of plating efficiency on ßTCP scaffolds
The Alamar Blue assay is relatively insensitive at low cell numbers. Hence to determine the
plating efficiency of cells on control and tethered EGF crosses at early time points (12 and
24 hr), we developed a protocol to directly count cells that were fixed and DAPI-stained by
embedding crosses in agarose followed by a demineralization step to dissolve the cross, allow-
ing direct microscopic observation of the cells in situ. In these experiments, we used smaller
ßTCP cross-shaped scaffolds (dimensions: 3.6x3.6x1.8mm, Therilok II, Integra Life Sciences,
Plainsboro, NJ, USA) in order to have enough working distance to directly count all cells
adhered onto scaffolds (with 10x objective) using a demineralization protocol. Crosses were
fabricated by a process identical to that used for larger crosses, sterilized by autoclaving, and
then were treated according to the EGF tethering protocol described above, using PBS as a
control.
Crosses were placed in individual wells of a 96-well plated and seeded with 11,000 cells in
200uL of EX media leading to ~1,700–2,200 cells landing on the 3mm scaffold (based on pre-
dicted ~16–20% seeding efficiency for 3mm crosses placed in 96-well plates). Following culture
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for 12 or 24 hours in EX media, cells were rinsed with 1x PBS, fixed for 2 hours with 2% glutar-
aldehyde/2% formaldehyde in 1x PBS, then washed with multiple rinses in 1xPBS (3x; 30 sec-
onds each). Crosses were then embedded in agarose, demineralized in a mild HCl solution and
left at 4C until embedded scaffolds appeared translucent. The HCl solution was then neutral-
ized by multiple rinses with 1x PBS. The cells within the embedded scaffolds were stained with
DAPI and then imaged under a confocal microscope. Stacks were taken using a 10x objective
using the DAPI filter. Z-stacks covered a z-range of 1.8mm (ßTCP scaffold height = 1.6mm)
and an XY Z-stack sweep covered a total area of ~4x4mm range on the XY axis (total area
scanned 4.4x4.4x1.8mm). Stacks along the XY axes covering the complete cross were acquired
and cells in each stack were counted using the DAPI signal and the spots function in the IMA-
RIS imaging software (Bitplane; South Windsor, CT, USA).
Results
ßTCP binding peptides identified by phage display
Three rounds of panning yielded plaques for three of the six conditions: ßTCP blocked with
BSA; ßTCP blocked with OBB buffer (non-mammalian blocking buffer); and ßTCP-PLGA
composite blocked with OBB buffer. Mock conditions (tubes only) and ßTCP-PLGA blocked
with albumin (BSA) did not yield plaques at the 2nd and 3rd round respectively. The sequence
Leu-Leu-Ala-Asp-Thr-Thr-His-His-Arg-Pro-Trp-Thr was identified in a total of 28% (8/29) of
the clones: 5 from ßTCP blocked with BSA; 2 from ßTCP blocked with OBB protein buffer and
1 from composite ßTCP-PLGA blocked with OBB buffer, (Fig 2A). The remaining 21 clones
showed only modest sequence similarity based on the BLOSUM62 scores (Fig 2A).
The 12-amino acid consensus sequence (Mw = 1448 Da) includes one negatively charged
residue (Asp), one positively-charged residue (Arg), and has a predicted pI of 6.92. Interest-
ingly, the sequence includes two histidines (nominal pK of 6.1), which may become protonated
in the low-pH environment of post-surgical inflammation or abstract protons from the calcium
phosphate surface. The peptide is predicted to be relatively soluble based on a grand average of
hydropathicity (GRAVY) score in the moderately negative range (-0.800). The extinction coef-
ficient (water) at 280 nm was determined to be 5500 M-1 cm-1.
Binding affinities of EGF fusion proteins with single and concatameric
ßTCP binding peptides
Based on the biophysics of interactions between the EGFR and tethered EGF, it is desirable to
present the EGF moiety using a spacer to enhance accessibility of the ligand [31,50,51]. We
therefore fused the binding peptide sequences to the N-terminus of human EGF (53 amino
acids; MW = 6.2KDa) with an intervening 106 amino acid sequence comprising a coiled-coil
sequence (46 amino acids, MW = 5.4 KDa) flanked on both ends by a flexible, protease-resis-
tant spacer (25 amino acids; MW = 1.9KDa) along with several restriction enzyme sites for
cloning (See S1 Table for protein sequence). In previous work, we used paired high-affinity het-
erospecific coiled-coil sequences with the same protease-resistant spacer in order to dimerize
EGF and other EGFR family ligands, and had determined that the fusion proteins and their
dimers were active when constructed as either N-terminal or C-terminal fusions [48].
Further, we reasoned that the binding affinity of the peptide to ßTCP might be further
enhanced by concatamerization of the binding sequence. We used mutagenesis (see Methods)
to concatamerize the 12-mer ßTCP binding peptide, yielding protein fusions with 3, 5, and 10
repeats of the 12 amino acid ßTCP binding unit (LLADTTHHRPWT) flanked by other rele-
vant protein domains as depicted in Fig 1 (see Methods). We first examined the relative
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binding affinities of the fusion proteins as a function of the number of repeats of the binding
domain in the fusion protein using a semi-quantitative approach based on eluting proteins fol-
lowed by western blot analysis (Fig 2B and 2C). We titrated the adsorption concentrations
across a range of 0–15 μM and found that binding exhibited a profound dependence on the
number of 12-mer repeats (3, 5 or 10) in the binding domain (Fig 2B and 2C). Based on these
results, we selected the fusion protein with the 10x linear concatamer, referred to as BP10-
T-EGF (See Fig 1), to perform all subsequent cell interaction experiments.
BP10-T-EGF in solution exhibits wild-type soluble EGF activity
After selecting BP10-T-EGF as the best binder, we confirmed the purity and activity of each
recombinantly-produced 10-mer protein batch prior to use in cell phenotypic assays. Western
blots of samples subjected to SDS-PAGE showed that the EGF is co-localized with the 73 kDa
band (Fig 3A), as expected for intact BP10-T-EGF. Biological activity of BP10-T-EGF compared
to control wild type EGF was assessed by analyzing activation of Erk-1 and Erk-2 (Erk1/2), a
signaling pathway that shows maximal phosphorylation 7–15 min after stimulation of EGFR
in MSC [20,30,31,50–53]. Compared to unstimulated controls, a 2.5 to 3-fold increase in
ERK1/2 phosphorylation was observed 10 min after stimulation of MSC by either wild type
EGF or BP10-T-EGF (Fig 3B). Results were normalized to the loading control GAPDH (N = 3
per condition; one-way ANOVA p<0.0001; pairwise comparisons with control were p0.001
using Tukey’s multiple comparisons test; all data was log-transformed before analysis). There
was no statistical difference between the pairwise comparisons of wild type EGF and soluble
BP10-T-EGF (p>0.05; Tukey’s test). Thus, the EGF domain in BP10-T-EGF appears to be fully
competent to activate the EGFR.
Fig 2. Identification of ßTCP-binding peptide and concatamerization of the sequence in EGF fusion proteins. Sequence alignment of multiple panning
experiments against ßTCPmaterial using orthogonal blocking and panning against composite ßTCP-PLGA substrates showing that the consensus
sequence in 8 of 29 clones is LLADTTHHRPWT (A). Anti-EGF immunoblot performed against scaffold-eluted BPn-T-EGF fusion protein with different binding
peptide repeats (n = 3, 5 and 10) tethered at dilutions as indicated, illustrating greater tethering with increase n repeats of the binding peptide in the
concatamer (B). Quantification of anti-EGF immunoblot signals depicted in 2B shows that the 10-mer repeat of the 12-amino acid ßTCP-binding peptide
imparts the highest affinity binding to the BPn-T-EGF fusion protein (C).
doi:10.1371/journal.pone.0129600.g002
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Binding and release of BP10-T-EGF tethered to ßTCP scaffolds
Comparable binding isotherms for BP10-T-EGF were observed for crosses of 3 mm and 5 mm
using concentrations of 0.2–9 μM soluble protein (Fig 4A). The resulting range of tEGF surface
densities was estimated as 4,000–45,000 EGF/μm2 (see Methods), well within and above the
value of 500–5,000 EGF/μm2 found to provide maximal stimulation to epithelial and mesen-
chymal cells in previous studies employing EGF tethered to polymer substrates [31,50,51].
However, because these previous studies employed tethering schemes that fostered local clus-
tering of tethered EGF, and the binding peptide approach would not necessarily lead to such
localized clustering, a tethering concentration of 2 μM (~ 10,000 EGF/μm2) was chosen for fur-
ther studies. After a 7-day long incubation of treated (2 μM) scaffolds in 1xPBS at 37C, a ~25%
release of tethered BP10-T-EGF protein was observed (N = 4 per condition, Fig 4B). Another
stability experiment performed at lower temperatures (4C) using the same buffer revealed
there was no statistically significant release of BP10-T-EGF protein from 3mm ßTCP scaffolds
Fig 3. BP10-T-EGF fusion proteins activate EGFR.Coomasie blue staining of purified BP10-T-EGF by
SDS-PAGE shows a single predominant band at the expected molecular weight (73 KDa), and this band
contains the EGF immunoreactive activity (A) Soluble BP10-T-EGF elicits phosphorylation of ERK 1 and 2 in
a comparable fashion to wild type EGF (B).
doi:10.1371/journal.pone.0129600.g003
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(Normalized protein amounts were 1.02 +- 0.09 (day 0) and 1.02 +- 0.11 (day 5); both were
normalized to t = 0; N = 3 per condition).
Tethered EGF stimulates an increase in hBMSC number on scaffolds
following 7-day culture
After establishing that the EGF domain of the BP10-T-EGF fusion protein induced bioactivity
when it was used in soluble form for MSC stimulation (activation of signaling pathways down-
stream of activated EGFR), we investigated phenotypic responses of low passage primary
hBMSC cultured on ßTCP scaffolds modified with BP10-T-EGF fusion protein for three differ-
ent densities of adsorbed BP10-T-EGF fusion protein. We have previously shown that EGF
tethered to polymer substrates via polyethylene oxide (PEO) tethers can enhance proliferation
of hBMSC maintained in both expansion and osteogenic media [34] We used day 7 as a metric
for comparison in order to allow for several MSC population doublings [54].
Scaffolds (ßTCP crosses, see Methods) were pre-incubated with BP10-T-EGF solutions at
concentrations of 0.4 μM, 2 μM, and 9 μM in order to achieve a range of surface densities (esti-
mated as 4,000–45,000 BP10-T-EGF per μm
2) and to determine dose response. Human BMSCs
Fig 4. Binding of BP10-T-EGF to ßTCP scaffolds and elution over 7 days. Binding isotherms of BP10-
T-EGF for 5mm and 3mm crosses (A). Analysis of released and bound BP10-T-EGF protein for the 2μM
tethering condition shows that assays are robust (i.e., the combined bound and released at 7 days is
statistically indistinguishable from the initial amount) and that 75% of the BP10-T-EGF fusion protein remains
bound to the scaffold after a 7-day incubation in 1xPBS at 37°C (B).
doi:10.1371/journal.pone.0129600.g004
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were seeded onto the treated and control scaffolds and cultured for 7 days in expansion
medium. After 7 days, the relative cell numbers were quantified using the Alamar Blue reagent,
using cells seeded on standard plates at different densities as a calibration to ensure the assay
was in the linear range. All scaffolds treated with BP10-T-EGF had a 2–2.3 fold greater number
of hBMSC number compared to surfaces without BP10-T-EGF (Fig 5A; N = 3 per condition;
one-way ANOVA p-value<0.05 (p-value = 0.02); all pairwise p-values of BP10-T-EGF vs con-
trol were<0.05 using Tukey’s multiple comparison test). No statistical differences were
observed between the different BP10-T-EGF surface densities (All pairwise p-values>0.05
using Tukey’s test). These results indicate that EGF-tethered onto ßTCP scaffolds does not
impair expansion of hBMSCs, as the final cell number was greater than the initial number
(data not shown), but these data are not sufficient to conclude that tethered EGF enhances pro-
liferation, as differences in initial plating efficiencies together with comparable expansion rates
Fig 5. Tethered BP10-T-EGF induces in vitro expansion of hBMSCs cultured on ßTCP scaffolds.Cells
were seeded on control and BP10-T-EGF- treated scaffolds, cultured in expansion medium for 7 days and
then subjected to Alamar blue assay to assess cell numbers relative to controls. A 2–2.3 fold increase in total
hBMSC number was observed across three different tethered BP10-T-EGF surface densities (N = 3 per
condition; one-way ANOVA p-value<0.05 (p-value = 0.02); all pairwise p-values of tethered EGF vs control
were <0.05 using Tukey’s multiple comparison test) (A). To parse effects that tethered EGFmight have on
plating efficiency, MSCs were cultured on ßTCP scaffolds for 12–24 hr and the number of attached cells was
then determined using a visual count of nuclei following acid demineralization of agarose-embedded
scaffolds. Results from 12-hr and 24-hr cell culture revealed no statistical difference (n.s.; N3 per condition;
One-way ANOVA p-value>0.05) in the number of hBMSCs as a function of condition, indicating that tethered
EGF is not altering the plating efficiency (B).
doi:10.1371/journal.pone.0129600.g005
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may account for the observed differences at day 7. To parse these mechanisms, we next exam-
ined plating efficiencies.
Tethered EGF does not alter plating efficiency of hBMSCs seeded on
ßTCP scaffolds
The Alamar Blue assay and other similar kinds of proliferation assays do not have sufficient
sensitivity to detect the relatively small number of cells present on scaffolds immediately after
seeding. Hence, we developed an approach to directly count cells seeded on scaffolds by
embedding scaffolds in agarose, demineralizing to reveal an optically-clear mold, then staining
cells and observing them with confocal microscopy. Using this method, we found no statistical
differences between the direct count of P3 hBMSCs in the control or BP10-T-EGF conditions
for both the 12hr and 24hr time point (Fig 5B). This suggests that the increase in hBMSC num-
ber observed after a 7-day culture under BP10-T-EGF conditions was most likely due to induc-
tion of proliferation and not due to differential plating efficiency.
Discussion
Here we demonstrate the use of a ßTCP-binding peptide discovered through phage display
and concatamerized to improve its affinity, to reliably tether EGF onto ßTCP scaffolds for
stimulation of hBMSCs. This high-affinity, concatamerized binding peptide domain is of mod-
erate size (120 amino acids, ~14 kDa), and does not contain unnatural amino acids or post-
translational modifications like other ceramic or apatite binders [55–57], making it compatible
with standard protein production and manufacturing strategies. This facile tethering approach
only requires incubation of the fusion protein (see Fig 1) with the ßTCP substrate and subse-
quent washings to remove excess unbound protein. This approach thus allows for easy modifi-
cation of ßTCP bone void filler scaffolds with bioactive ligands that can enhance the survival,
proliferation or differentiation of tissue-resident or transplanted osteoprogenitors (i.e. MSCs
and CTPs; [4,7,8,18,58].
We focused on EGF as the fusion partner for the ßTCP-binding peptide motif because of
the multifaceted roles EGFR plays in bone development and homeostasis in vivo, together with
previous studies demonstrating that EGF exerts beneficial effects on migration, colony forma-
tion, and, proliferation of bone marrow-derived CTPs when covalently tethered to model poly-
mer surfaces [31–34,51]. Simple adsorption of EGF to the scaffold is not a reliable approach for
bioactive delivery of EGF for this application. We could not detect binding of EGF fusions lack-
ing the ßTCP-binding domain, an observation consistent with reports that wild-type EGF does
not bind hydroxyapatite [57], a material with composition and surface charge similar to ßTCP
[59], likely due to repulsion as both possess negative surface charges around the same order of
magnitude [59,60].
We observed retention of ßTCP-bound BP10-T-EGF bioactivity across a range of surface
densities (estimated as 4,000–45,000 EGF/μm2) as assessed by enhancement of MSC prolifera-
tion (Fig 5A). We investigated this range based on previous reports that tethered EGF enhances
survival, proliferation, and colony formation by MSCs and CTPs when tethered to polymer
surfaces at densities of ~5,000 EGF/μm2 [31–34,51]. We did not observe a statistically-signifi-
cant effect of tethered EGF density on proliferation in the range of 4000–45,000 EGF/μm2, but
this is not surprising as tethered EGF densities as low as ~400 tethered EGF/μm2 induce maxi-
mal DNA synthesis in primary hepatocytes and low as ~700 tethered EGF/μm2 induces maxi-
mal response in fibroblasts and keratinocytes [50,57,61]). We note that we attribute the
increase in cell number to proliferation rather than enhanced initial attachment, as assessment
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of cell numbers present on the scaffolds by direct visual counting of nuclei at 12 and 24 hr
post-seeding showed no statistical difference among conditions.
Although we did not directly measure the release and consumption of tethered EGF in
the presence of cells, the finding of enhanced proliferation over 7 days together with observa-
tions that 75% of the protein was still retained after 7 days of incubation in PBS at 37ºC (Fig
4B) suggest that the tethered protein remains active for at least several days in culture. There
are two primary mechanisms of BP10-T-EGF release. ßTCP exhibits small but non-zero solu-
bility over a broad range of pH values, thus some small amount of BP10-T-EGF release is
expected to occur due to surface dissolution of the ßTCP (solubility limit at ~0.0005 g/L as
reported by [62]). However, by calculating the solubility limit at 200uL (volume of 96 well
plates, corresponds to 0.1 micrograms of ßTCP) and using both the surface area of the scaffolds
(0.244 m2/gram; Hg porosimetry) and the initial BP10-T-EGF surface density (~19 micrograms
at 2uM tethering), we estimate that only about 100 picograms of protein are released due to
surface dissolution. Since the amounts we tether are in the microgram range, we believe tran-
sient unbinding of the concatemer region from the surface of ßTCP coupled to extracellular
factors play a bigger role in release.
The success of using a filamentous phage display library to obtain high affinity binders is
not assured, as material properties, panning protocols, peptide length and library size can be
limiting factors. However, reasonably high affinity binders to a variety of surfaces, including
polymers, metals and, ceramics have been identified through commercial and non-commercial
libraries [42–44,63–69]. Variations in display strategies include the number of peptides pre-
sented per phage, cyclized vs linear presentation, and peptide lengths [42,70,71]. Each mode of
presentation has advantages and disadvantages with respect to library size, valency of display,
and structural flexibility of peptides. Due to the polyvalent nature of M13 p3 and p8 phage dis-
play, avidity can play a role in binding as p3 display offers 3–5 copies of the peptide and p8 dis-
play offers ~2700 copies [72–75]. This polyvalency can lead to a higher apparent affinity of the
phage clones due to avidity, which leads to reduced binding once the monovalent peptides are
cloned and expressed.
Typical binder affinities of monovalent peptides from panning experiments with commer-
cial kits tend to be in the low μM to mid nM range [44,76–78]. Typically, 3 to 5 rounds of
screening are sufficient to obtain binders with desired affinities [42–44,68]. Additional rounds
(>4) may introduce phage-specific factors (e.g. phage replication) that reduce the sequence
diversity with minimal increase in affinity of the peptide pool [79,80]. After 3 rounds of pan-
ning against ßTCP using the 12-aa p3 M13 phage display kit (see Methods) we obtained 9–30
plaques per panning condition, except on tube controls which did not yield plaques at round 3.
After sequencing 9–10 phage plaques per condition, we found a consensus ßTCP binding
sequence (LLADTTHHRPWT) that was present in 8 out of 29 clones. Importantly, this con-
sensus sequence emerged across orthogonal ßTCP blocking conditions (BSA and OBB) as well
as panning against a composite of ßTCP with the degradable polyester biomaterial PLGA, sug-
gesting it is highly specific for the target. We then created a fusion protein comprising this 12
amino acid peptide fused to human EGF via protease-resistant spacer flanking a coil-coil motif
[48] and expressed the protein with a MBP motif to increase solubility of the purified final pro-
tein product. This first generation fusion protein did not exhibit the desired high affinity bind-
ing to ßTCP, presumably because the 12 amino acid peptide alone could not offset the
thermodynamic driving force for the 73,000 dalton molecular weight protein (including the
MBP domain) to remain soluble.
We thus exploited a polyvalency approach in which created a linear concatamerization of
the binding peptide to increase the driving force for surface adsorption. Sequential increases of
the number of 12-mer binding peptide sequences in the concatamer, from 3 to 5 to 10, were
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associated with increased affinity of the fusion protein with the ßTCP surface (Fig 2B and 2C).
The repeat number is representative of the lower and higher bounds of p3 peptide copies per
phage (i.e., 3- and 5- mer [72–74]), while the 10-mer is a greater valency than the p3 display
could theoretically offer. Linear concatamerization has previously been used with some success
to increase binding peptide affinity [68], but is not a general approach that works with all pep-
tides tested. Intuitively, the domain spacing must align with multiple repeats of the affinity tar-
get on the surface in order to maintain multiple high affinity contacts. We did not
systematically investigate the role of domain spacing by varying the linker length between
concatenated peptide sequences, but speculate that further improvements in affinity could be
achieved by changing this variable.
Many features of the 12 amino acid binding sequence we identified are consistent with affin-
ity for calcium phosphate. Portions of the LLADTTHHRPWT sequence serve as common
motifs found in proteins with affinity for binding to phosphate-containing compounds (i.e.
ATP/ADP/AMP/UDP, Phosphoglyceric acid (PGA), DNA and tRNA, among others), with 13
out of the top 15 hits on a BLAST search illustrating such binding capabilities or ability to bind
to divalent calcium. Amino acids present in the mid-portion of our peptide (DTTHHR)—
including aspartic acid, threonine, histidine, and arginine—are all capable of forming hydrogen
bonds and were prominently implicated in the interactions with phosphate groups within the
active site of several of the enzyme families from the BLAST results (PDB ID#s: 1JJV, 4I1V,
4DEC, and 3V4R; [81,82]). The TT motif has been implicated in the interactions of depho-
spho-CoA kinases with the diphosphate group of adenosine di-phosphate (ADP) through
hydrogen bonding mechanisms (PDB ID#s: 1JJV, 4I1V; [83]), suggesting a potential role for
the TT motif in our binding peptide for interaction with calcium phosphate. Further, amino
acids with basic side or acidic chains like arginine and aspartic acid can form salt bridges with
the phosphate and calcium ions, respectively. Aspartic acid residues, along with glutamate and
carboxy-glutamate residues in proteins are known to be able to form coordination complexes
with calcium ions in solution [84]. There are several hydroxyapatite (HA) and calcium phos-
phate binding peptides that contain streaks of or domains rich in acidic amino acids [85–89].
Some of these are based on binding domains from proteins found in bone matrix like bone sia-
loproteins, osteonectin, among others [86,87,90–92]. Histidine residues can coordinate with
divalent cations like Ca+2 [81], and both histidine and aspartic acid residues have been specu-
lated to accelerate nucleation of calcium phosphates (CaP) by removing protons from phos-
phate groups during the hydrogen bonding reaction [93].
We speculate that the central 6aa polar domain in the binding peptide dominates the ener-
getics of interactions with the surface, with the flanking hydrophobic amino acids (LLA on N-
terminus; and PW on the C-terminus) providing some conformational support or shielding
water molecules away from the surface to strengthen surrounding hydrogen bonds. However,
mutational analysis would be required to precisely detail the role of individual or group of
amino acids. Such analysis in other systems often reveals that only a few amino acids are crucial
for binding, and the surrounding amino acids often provide support (structural or chemical) to
optimize the interactions of those critical residues with the surface [44,45,66,69,94,95].
Taken together, these results provide compelling motivation for ongoing efforts to assess
the colony-forming performance of BP10-T-EGF scaffolds with human bone marrow samples,
and to translate the in vitro findings to in vivo bone healing models employing transplants of
aspirated marrow, such as those in the canine femoral defect model [47]. Future studies
might also address alterations in the protein design to improve expression and purification
properties.
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Conclusion
We showed that a phage display-derived, concatamerized ßTCP binding peptide comprising
12 amino acids is sufficient to tether EGF onto ßTCP scaffolds in a stable manner in a fusion
protein construct, and that the tethered EGF is active as assessed by MSC proliferation. The
concatamerized binding peptide shows high-affinity towards ßTCP and can be used to tether
other growth factors or bioactive ligands. This provides a versatile foundation for controlled,
single or multi-protein delivery on ßTCP-based bone grafting materials.
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